Influenza Vaccination Strategy for Patients With Hematologic Malignancy

NCT07485855 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Neoplasms
Influenza
Immunogenicity

Interventions

BIOLOGICAL: High-dose trivalent inactivated influenza vaccine (HD-IIV3)
BIOLOGICAL: MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4)
BIOLOGICAL: Standard-dose trivalent inactivated influenza vaccine (SD-IIV3)

Sponsor

Asan Medical Center